Literature DB >> 19937164

A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients.

Bo Ye1, Shu-Geng Gao, Wang Li, Long-Hai Yang, Shou-Hua Zhao, Ke Ma, Xiao-Lei Zhu, Xiang-Yang Liu, Ke-Ling Sun.   

Abstract

Castleman's disease (CD) is a rare disorder characterized by non-cancerous tumor growth that may develop in the lymph node tissue at a single site or throughout the body (Castleman et al. in Cancer 9:822-830, 1956). It involves hyperproliferation of specific B cells that produce the cytokine IL-6. This disorder is often undiagnosed or misdiagnosed. For this reason, only very few patients have been reported, and little information is available in the literature. In hopes of providing a better understanding of this rare disease, this report examines 52 patients with Unicentric Castleman's disease (UCD) and Multicentric Castleman's disease (MCD) treated from 1999-2008 at a single institution. Fifty-two patients with CD, along with their histological diagnoses, were collected. Patients were divided into two groups--the more common UCD and the less common MCD. Relevant clinical, pathological, and laboratory data were examined in order to evaluate treatment responses, with symptom onsets and survival period serving as the endpoints of the assessment. Each of the 48 patients with UCD exhibited benign symptoms and underwent a curative surgical resection with excellent prognosis. All of the four patients with MCD received surgical resection. Three of the four patients relapsed and received radiotherapy and/or chemotherapy. Only one of the three post-treatment patients survived. UCD is manifested in the form of benign, painless, slow lymph node enlargement that is generally asymptomatic. Complete surgical removal is recommended as a course of curative treatment. The multicentric form of CD exhibits a progressive clinical course with potential for malignancy. There is currently no standard therapy for MCD.

Entities:  

Mesh:

Year:  2009        PMID: 19937164     DOI: 10.1007/s12032-009-9355-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  Progressive transformation of germinal center presenting with histological features of hyaline-vascular type of Castleman's disease.

Authors:  Masaru Kojima; Shigeo Nakamura; Shuuichi Miyawaki; Yoshihiro Ohno; Noriyuki Sakata; Nobuhide Masawa
Journal:  APMIS       Date:  2005-04       Impact factor: 3.205

Review 2.  Castleman's disease and related disorders.

Authors:  G Frizzera
Journal:  Semin Diagn Pathol       Date:  1988-11       Impact factor: 3.464

3.  Plasma cell giant lymph node hyperplasia responding to radiation therapy.

Authors:  D G Nordstrom; H H Tewfik; H B Latourette
Journal:  AJR Am J Roentgenol       Date:  1978-01       Impact factor: 3.959

Review 4.  Multicentric Castleman's disease.

Authors:  B A Peterson; G Frizzera
Journal:  Semin Oncol       Date:  1993-12       Impact factor: 4.929

Review 5.  [Castleman's disease].

Authors:  C Larroche; P Cacoub; P Godeau
Journal:  Rev Med Interne       Date:  1996       Impact factor: 0.728

6.  Pathologic quiz case 2. Castleman disease (giant lymph node hyperplasia).

Authors:  K Gangopadhyay; Z Z Mahasin; H Kfoury
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1997-10

7.  Castleman disease. Unusual retroperitoneal location indistinguishable from malignant tumor in preoperative angiographic appearance.

Authors:  H Takihara; G Yamakawa; Y Baba; M Takahashi; T Ishihara
Journal:  Urology       Date:  1993-02       Impact factor: 2.649

8.  Imaging features of atypical thoracic Castleman disease.

Authors:  Sheung-Fat Ko; Yung-Liang Wan; Shu-Hang Ng; Jui-Wui Lin; Ming-Jeng Hsieh; Fu-Min Fang; Tze-Yu Lee; Wei-Jen Chen
Journal:  Clin Imaging       Date:  2004 Jul-Aug       Impact factor: 1.605

Review 9.  Retroperitoneal Castleman's disease.

Authors:  J L Seco; F Velasco; J S Manuel; S R Serrano; L Tomas; A Velasco
Journal:  Surgery       Date:  1992-11       Impact factor: 3.982

Review 10.  Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome.

Authors:  Hongbei Wang; Rosemary L Wieczorek; Michael E Zenilman; Fidelina Desoto-Lapaix; Bimal C Ghosh; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2007-11-20       Impact factor: 2.754

View more
  21 in total

Review 1.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

Review 2.  Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

Authors:  Shou-Hui Zhu; Yong-Hua Yu; Yong Zhang; Ju-Jie Sun; Da-Li Han; Jia Li
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

3.  Clinicopathological Profile of Castleman's Disease in Indian Population: Experience From a Tertiary Care Center.

Authors:  Ashok Singh; Suvendu Purkait; Saumyaranjan Mallick; Prashant Ramteke; Chandan Krushna Das; Ajay Gogia; Maher Chand Sharma; Lalit Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-25       Impact factor: 0.900

4.  A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution.

Authors:  Jin-Peng Jiang; Xiao-Fei Shen; Jun-Feng Du; Wen-Xian Guan
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

5.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

6.  Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients.

Authors:  A J Hill; S H Tirumani; M H Rosenthal; A B Shinagare; R D Carrasco; N C Munshi; N H Ramaiya; S A Howard
Journal:  Br J Radiol       Date:  2015-02-24       Impact factor: 3.039

7.  A retrospective study of 44 patients with head and neck Castleman's disease.

Authors:  Taiqin Wang; Xiaoqiang Chen; Wei Chen; Liangwen Shi; Jianzhi Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-09-04       Impact factor: 2.503

8.  Multicentric Castleman's disease in a Ghanaian adult.

Authors:  Y A Dei-Adomakoh; C Segbefia; I Ekem; A Taylor
Journal:  Ghana Med J       Date:  2013-06

Review 9.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Authors:  Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Insights Imaging       Date:  2021-03-11

10.  Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature.

Authors:  Chance Matthiesen; Rajeev Ramgopol; Jonathan Seavey; Salahuddin Ahmad; Terence Herman
Journal:  Radiol Oncol       Date:  2012-01-02       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.